Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:40 p.m.

    📋 Aurinia Pharmaceuticals Inc. (AUPH) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 06:07:35

    Event Type: Financial Results

    Event Details:

    Aurinia Pharmaceuticals Inc (AUPH) Reports Q3 2022 Financial Results Aurinia Pharmaceuticals Inc (AUPH) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 64180
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 151632
      • anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information. All forward-looking information contained in this press release is qualified by this cautionary statement. Additional informationrelated to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.Investor/Media Contact: DeDe Sheel Vice President, Investor Relations, Auriniadsheel@auriniapharma.com4AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)June 30, 2022
      • expected by the end of Q3 2022
      • expected on or prior to July 26, 2023

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 17.42K 12.51K $4.92K +39.30%
    Property Equipment Net 4.18K 4.42K $-235.00 -5.32%
    Current Liabilities Operating Lease Liabilities 953.00 1.06K $-106.00 -10.01%
    Noncurrent Liabilities Operating Lease Liabilities 7.43K 7.68K $-249.00 -3.24%
    Operating Expenses Selling General Administrative 44.32K 96.73K $-52.41K -54.18%
    Total Other Income Expense -967.00 958.00 $-1.93K -200.94%
    Loss From Operations -47.13K -73.87K $26.74K +36.19%
    Interest Income 142.00 745.00 $-603.00 -80.94%
    Net Loss -47.01K -47.01K $0.00 +0.00%
    Prepaid Expenses and Other Current Assets 12.51K 12.51K $0.00 +0.00%
    Property and Equipment, Net 4.42K 4.42K $0.00 +0.00%
    Intangible Assets, Net 8.40K 8.40K $0.00 +0.00%
    Accounts Payable 34.95K 34.95K $0.00 +0.00%
    Operating Lease Liabilities 1.06K 1.06K $0.00 +0.00%
    Revenue 6.59K 6.59K $0.00 +0.00%
    Selling, General & Administrative 44.32K 96.73K $-52.41K -54.18%
    Loss from Operations -47.13K -73.87K $26.74K +36.19%
    Interest Income 142.00 745.00 $-603.00 -80.94%
    Net Loss -46.99K -73.13K $26.13K +35.74%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Aurinia Pharmaceuticals Inc
    • CIK: 0001600620
    • Ticker Symbol: AUPH
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories